Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Brayan Murillo-Castillo"'
Autor:
Luis Castillo-Henríquez, Brayan Murillo-Castillo, Lexi Chaves-Siles, Juan José Mora-Román, Nils Ramírez-Arguedas, Édgar Hernández-Mora, José Vega-Baudrit
Publikováno v:
Scientia Pharmaceutica, Vol 90, Iss 2, p 34 (2022)
This review aims to present the Quality by Design (QbD) model as a suitable methodology to perform research in the academic Costa Rican institutions that teach Pharmacy. Pubmed, Science Direct, and Google Scholar databases were screened for original
Externí odkaz:
https://doaj.org/article/c8c2caf31f0d479390987980f928f2d0
Autor:
Luis Castillo-Henríquez, Pablo Sanabria-Espinoza, Brayan Murillo-Castillo, Gabriela Montes de Oca-Vásquez, Diego Batista-Menezes, Briner Calvo-Guzmán, Nils Ramírez-Arguedas, José Vega-Baudrit
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2100 (2021)
Chronic and non-healing wounds demand personalized and more effective therapies for treating complications and improving patient compliance. Concerning that, this work aims to develop a suitable chitosan-based thermo-responsive scaffold to provide 24
Externí odkaz:
https://doaj.org/article/40cec1509e814401ac8af4bfe5ecf4dd
Autor:
Nils Ramírez-Arguedas, Briner Calvo-Guzmán, José Vega-Baudrit, Pablo Sanabria-Espinoza, Brayan Murillo-Castillo, Gabriela Montes de Oca Vásquez, Diego Batista-Menezes, Luis Castillo-Henríquez
Chronic and non-healing wounds demand personalized and more effective therapies for treating complications and improve patient adherence. This work aims to develop a suitable chitosan-based scaffold to provide 24 hours controlled release of DKT, by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23909fa57291cbe6d3e0992fc95903a
https://doi.org/10.20944/preprints202110.0021.v1
https://doi.org/10.20944/preprints202110.0021.v1
Autor:
Álvaro Esteban Alfaro Alfaro, Brayan Murillo Castillo, Eugenia Cordero García, Javier Tascón, Ana I. Morales
Publikováno v:
Pharmacy. 10:95
Currently, metastatic colon cancer is treated with monotherapeutic regimens such as folinic acid, fluorouracil, and oxaliplatin (FOLFOX), capecitabine and oxaliplatin (CapeOX), and leucovorin, fluorouracil, and irinotecan hydrochloride (FOLFIRI). Oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9df7f76cddda0255de0f46c27808d67
https://doi.org/10.3390/pharmacy10040095
https://doi.org/10.3390/pharmacy10040095